BAYER AG-REG (BAYN.DE) Stock Fundamental Analysis
Europe - FRA:BAYN - DE000BAY0017 - Common Stock
27.85 EUR
+0.47 (+1.72%)
We assign a fundamental rating of 3 out of 10 to BAYN. BAYN was compared to 49 industry peers in the Pharmaceuticals industry. BAYN may be in some trouble as it scores bad on both profitability and health. BAYN has a bad growth rate and is valued cheaply.
1. Profitability
1.1 Basic Checks
In the past year BAYN was profitable.
BAYN had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BAYN reported negative net income in multiple years.
Each year in the past 5 years BAYN had a positive operating cash flow.
1.2 Ratios
BAYN has a Return On Assets of -3.25%. This is in the lower half of the industry: BAYN underperforms 69.39% of its industry peers.
Looking at the Return On Equity, with a value of -11.25%, BAYN is doing worse than 69.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.25% | ||
| ROE | -11.25% | ||
| ROIC | N/A |
ROA(3y)-0.5%
ROA(5y)-1.93%
ROE(3y)-2.08%
ROE(5y)-7.52%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BAYN's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 54.95%, BAYN is doing worse than 69.39% of the companies in the same industry.
In the last couple of years the Gross Margin of BAYN has declined.
The Profit Margin and Operating Margin are not available for BAYN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.95% |
OM growth 3Y-18.1%
OM growth 5Y-4.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.21%
GM growth 5Y-1.81%
2. Health
2.1 Basic Checks
BAYN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BAYN remains at a similar level compared to 1 year ago.
BAYN has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for BAYN has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.78, we must say that BAYN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.78, BAYN is doing worse than 71.43% of the companies in the same industry.
BAYN has a debt to FCF ratio of 8.37. This is a slightly negative value and a sign of low solvency as BAYN would need 8.37 years to pay back of all of its debts.
The Debt to FCF ratio of BAYN (8.37) is comparable to the rest of the industry.
BAYN has a Debt/Equity ratio of 1.04. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.04, BAYN is not doing good in the industry: 67.35% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.04 | ||
| Debt/FCF | 8.37 | ||
| Altman-Z | 0.78 |
ROIC/WACCN/A
WACC6.05%
2.3 Liquidity
BAYN has a Current Ratio of 1.13. This is a normal value and indicates that BAYN is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of BAYN (1.13) is worse than 71.43% of its industry peers.
BAYN has a Quick Ratio of 1.13. This is a bad value and indicates that BAYN is not financially healthy enough and could expect problems in meeting its short term obligations.
BAYN has a worse Quick ratio (0.73) than 75.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.13 | ||
| Quick Ratio | 0.73 |
3. Growth
3.1 Past
BAYN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.36%.
Measured over the past years, BAYN shows a decrease in Earnings Per Share. The EPS has been decreasing by -5.27% on average per year.
Looking at the last year, BAYN shows a decrease in Revenue. The Revenue has decreased by -1.99% in the last year.
Measured over the past years, BAYN shows a small growth in Revenue. The Revenue has been growing by 1.37% on average per year.
EPS 1Y (TTM)-16.36%
EPS 3Y-8.12%
EPS 5Y-5.27%
EPS Q2Q%30.85%
Revenue 1Y (TTM)-1.99%
Revenue growth 3Y1.87%
Revenue growth 5Y1.37%
Sales Q2Q%-3.63%
3.2 Future
BAYN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.05% yearly.
Based on estimates for the next years, BAYN will show a small growth in Revenue. The Revenue will grow by 1.19% on average per year.
EPS Next Y-6.48%
EPS Next 2Y-1.54%
EPS Next 3Y2.06%
EPS Next 5Y3.05%
Revenue Next Year-1.18%
Revenue Next 2Y-0.09%
Revenue Next 3Y0.7%
Revenue Next 5Y1.19%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 5.56, the valuation of BAYN can be described as very cheap.
BAYN's Price/Earnings ratio is rather cheap when compared to the industry. BAYN is cheaper than 93.88% of the companies in the same industry.
BAYN's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.20.
A Price/Forward Earnings ratio of 5.69 indicates a rather cheap valuation of BAYN.
93.88% of the companies in the same industry are more expensive than BAYN, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of BAYN to the average of the S&P500 Index (22.70), we can say BAYN is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.56 | ||
| Fwd PE | 5.69 |
4.2 Price Multiples
BAYN's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. BAYN is cheaper than 71.43% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BAYN indicates a rather cheap valuation: BAYN is cheaper than 97.96% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.96 | ||
| EV/EBITDA | 8.89 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.54%
EPS Next 3Y2.06%
5. Dividend
5.1 Amount
With a yearly dividend of 0.38%, BAYN is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 3.04, BAYN is paying slightly less dividend.
Compared to an average S&P500 Dividend Yield of 2.38, BAYN's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.38% |
5.2 History
The dividend of BAYN decreases each year by -45.34%.
Dividend Growth(5Y)-45.34%
Div Incr Years0
Div Non Decr Years3
5.3 Sustainability
BAYN has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-3.69%
EPS Next 2Y-1.54%
EPS Next 3Y2.06%
FRA:BAYN (9/18/2025, 12:38:16 PM)
27.85
+0.47 (+1.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners41.07%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap27.36B
Analysts71.43
Price Target29.09 (4.45%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.38% |
Yearly Dividend0.13
Dividend Growth(5Y)-45.34%
DP-3.69%
Div Incr Years0
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.87%
Min EPS beat(2)1.86%
Max EPS beat(2)45.89%
EPS beat(4)3
Avg EPS beat(4)8.47%
Min EPS beat(4)-17.26%
Max EPS beat(4)45.89%
EPS beat(8)6
Avg EPS beat(8)3.46%
EPS beat(12)8
Avg EPS beat(12)1.61%
EPS beat(16)12
Avg EPS beat(16)4.59%
Revenue beat(2)0
Avg Revenue beat(2)-1.8%
Min Revenue beat(2)-2.63%
Max Revenue beat(2)-0.98%
Revenue beat(4)1
Avg Revenue beat(4)-1.31%
Min Revenue beat(4)-3.42%
Max Revenue beat(4)1.79%
Revenue beat(8)2
Avg Revenue beat(8)-1.92%
Revenue beat(12)3
Avg Revenue beat(12)-2.37%
Revenue beat(16)7
Avg Revenue beat(16)-1.04%
PT rev (1m)0.67%
PT rev (3m)3.71%
EPS NQ rev (1m)-0.22%
EPS NQ rev (3m)19.4%
EPS NY rev (1m)2.38%
EPS NY rev (3m)2.38%
Revenue NQ rev (1m)0.23%
Revenue NQ rev (3m)-3.39%
Revenue NY rev (1m)-0.26%
Revenue NY rev (3m)-1.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.56 | ||
| Fwd PE | 5.69 | ||
| P/S | 0.59 | ||
| P/FCF | 5.96 | ||
| P/OCF | 3.83 | ||
| P/B | 0.9 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.89 |
EPS(TTM)5.01
EY17.99%
EPS(NY)4.9
Fwd EY17.58%
FCF(TTM)4.67
FCFY16.78%
OCF(TTM)7.28
OCFY26.13%
SpS47
BVpS30.91
TBVpS-18.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.25% | ||
| ROE | -11.25% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.95% | ||
| FCFM | 9.94% |
ROA(3y)-0.5%
ROA(5y)-1.93%
ROE(3y)-2.08%
ROE(5y)-7.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)7.82%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-18.1%
OM growth 5Y-4.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.21%
GM growth 5Y-1.81%
F-Score4
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.04 | ||
| Debt/FCF | 8.37 | ||
| Debt/EBITDA | 4.79 | ||
| Cap/Depr | 32.07% | ||
| Cap/Sales | 5.54% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 107.94% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.13 | ||
| Quick Ratio | 0.73 | ||
| Altman-Z | 0.78 |
F-Score4
WACC6.05%
ROIC/WACCN/A
Cap/Depr(3y)34.81%
Cap/Depr(5y)41.62%
Cap/Sales(3y)5.85%
Cap/Sales(5y)5.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.36%
EPS 3Y-8.12%
EPS 5Y-5.27%
EPS Q2Q%30.85%
EPS Next Y-6.48%
EPS Next 2Y-1.54%
EPS Next 3Y2.06%
EPS Next 5Y3.05%
Revenue 1Y (TTM)-1.99%
Revenue growth 3Y1.87%
Revenue growth 5Y1.37%
Sales Q2Q%-3.63%
Revenue Next Year-1.18%
Revenue Next 2Y-0.09%
Revenue Next 3Y0.7%
Revenue Next 5Y1.19%
EBIT growth 1Y-161.08%
EBIT growth 3Y-16.56%
EBIT growth 5Y-3.03%
EBIT Next Year63.3%
EBIT Next 3Y21.17%
EBIT Next 5Y10.79%
FCF growth 1Y1068.78%
FCF growth 3Y22.16%
FCF growth 5Y-3.69%
OCF growth 1Y169.98%
OCF growth 3Y12.83%
OCF growth 5Y-2.09%